Iba – Acquisition of own shares
Immediate release – March 7and2022
Louvain-la-Neuve, Belgium, March 7and2022 – Pursuant to Article 8:4 of the Royal Decree of 29 April 2019 implementing the Belgian Companies and Associations Code, Ion Beam Applications SA (“IBA”) hereby discloses information relating to its share buyback program. actions announced on December 3rd2021.
Under this program, IBA has asked a financial intermediary to buy back up to 400,000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement valid until June 30and2022, starting December 6and2021, to cover the remaining part of the company’s obligations under a long-term incentive plan granted to certain members of its staff in 2021.
Under this share buyback program, IBA bought back 54,774 IBA shares on Euronext Brussels during the period from February 28and,2022 until March 4 includedand2022, as follows:
The total number of shares purchased under this program therefore amounts to 384,405. Consequently, the current situation of treasury shares (held directly by IBA SA and indirectly via its subsidiary IBA Investments SCRL) is as follows.
IBA (Ion Beam Applications SA) is a global medical technology company focused on providing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the world technology leader in the field of proton therapy, considered the most advanced form of radiotherapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose between large-scale universal proton therapy centers as well as compact single-room solutions. In addition, IBA has a radiation dosimetry activity and develops particle accelerators for the medical world and industry. Based in Belgium and employing approximately 1,500 people worldwide, IBA has installed systems worldwide.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com
Press release EN 20220307